Zosano Pharma (ZSAN) Stock Price, News & Analysis

Company Overview

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: $0.52 to $112.00
• 52-Week Range: $0.46 to $37.45
• Volume: 5,685 shs
• Average Volume: 425,375 shs
• Market Capitalization: $980.40
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZSAN Stock Analysis - Frequently Asked Questions

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) issued its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by $0.01. Zosano Pharma had a negative trailing twelve-month return on equity of 177.06% and a negative net margin of 8,375.11%.

When did Zosano Pharma's stock split?

Zosano Pharma's stock reverse split before market open on Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Zosano Pharma IPO?

Zosano Pharma (ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

What other stocks do shareholders of Zosano Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zosano Pharma investors own include Tonix Pharmaceuticals (TNXP), NIO (NIO), Adamis Pharmaceuticals (ADMP), Bionano Genomics (BNGO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

Company Calendar

• Last Earnings: 5/13/2022
• Today: 1/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ZSAN
• CUSIP: N/A
• CIK: 1587221
• Web: www.zosanopharma.com
• Phone: (510) 745-1200
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($14.5034)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,920,000.00
• Net Margins: -8,375.11%
• Pretax Margin: -8,375.11%
• Return on Equity: -177.06%
• Return on Assets: -119.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.61
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $790,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.74 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,902,000
• Free Float: 4,784,000
• Market Cap: $980.40
• Optionable: Not Optionable
• Beta: 3.30